Table 1. Patient and Treatment Characteristics.
| IGRT Cohort | Non IGRT Cohort | ||||
|---|---|---|---|---|---|
| N=62 | N=107 | ||||
| N (%) | N (%) | P-value | |||
| Patient Characteristics | |||||
| Age | 0.45 | ||||
| Median | 63 | 61 | |||
| Range | 38-85 | 36-84 | |||
| ≥70 Years | 14 (22) | 25 (23) | |||
| ECOG | <0.0001 | ||||
| 0-1 | 50 (81) | 98 (92) | |||
| 2 | 12 (19) | 9 (8) | |||
| Race | 0.84 | ||||
| Caucasian | 49 (79) | 86 (80) | |||
| African-American | 13 (21) | 21 (20) | |||
| Sex | 0.40 | ||||
| Male | 45 (73) | 71 (66) | |||
| Female | 17 (27) | 36 (34) | |||
| Group Stage | 0.66 | ||||
| IIB | 1 (2) | 4 (4) | |||
| IIIA | 36 (58) | 57 (53) | |||
| IIIB | 25 (40) | 46 (43) | |||
| T Stage | 0.43 | ||||
| 1 | 10 (16) | 13 (12) | |||
| 2 | 22 (35) | 30 (28) | |||
| 3 | 11 (17) | 22 (21) | |||
| 4 | 17 (27) | 41 (38) | |||
| x | 2 (3) | 1 (1) | |||
| N Stage | 0.25 | ||||
| 0 | 6 (10) | 13 (12) | |||
| 1 | 3 (5) | 11 (10) | |||
| 2 | 36 (58) | 66 (62) | |||
| 3 | 17 (27) | 17 (16) | |||
| Histology | 0.05 | ||||
| Adenocarcinoma | 24 (39) | 28 (26) | |||
| Squamous Cell | 24 (39) | 42 (39) | |||
| Large Cell/Neuroendocrine | 3 (5) | 5 (5) | |||
| NSCLC NOS | 9 (15) | 32 (30) | |||
| Other/Unknown | 2 (3) | 0 (0) | |||
| Treatment Characteristics | |||||
| PET Planned | 62 (100) | 84 (79) | 0.0004 | ||
| 4D CT Planned | 62 (100) | 37 (35) | <0.0001 | ||
| Tissue heterogeneity corrections | 62 (100) | 26 (24) | <0.0001 | ||
| Radiation Dose | 0.06 | ||||
| Median | 70 Gy | 66 Gy | |||
| Range | 56-74 Gy | 45-76 (Gy) | |||
| ≥ 60 Gy | 61 (98) | 101 (94) | 0.42 | ||
| ≥ 70 Gy | 35 (55) | 41 (38) | 0.04 | ||
| Fraction Size | 0.06 | ||||
| Median (Range) | 2 Gy (2-2.7 Gy/Fx) | 2 Gy (1.5-2.7 Gy/Fx) | |||
| Chemotherapy (Any) | 62 (100) | 107 (100) | 1.0 | ||
| Induction † | 10 (16) | 30 (28) | 0.08 | ||
| Concurrent † | 62 (100) | 107 (100) | 1.0 | ||
| Adjuvant † | 8 (13) | 21 (20) | 0.30 | ||
| Chemotherapy Agent† | <0.0001 | ||||
| Carboplatin and Paclitaxel | 48 (77) | 70 (65) | |||
| Carboplatin/Cisplatin and Etoposide | 1 (2) | 5 (4.6) | |||
| Carboplatin and Pemetrexed | 9 (14) | 0 (0) | |||
| Carboplatin and Gemcitabine | 0 (0) | 14 (13) | |||
| Other/Unknown | 4 (6) | 18 (17) | |||
†
Percentages exclude patients not receiving chemotherapy.
Abbreviations: N=Number, %=Percent, Fx=Fraction, ECOG=Eastern Cooperative Oncology Group